Merck's Keytruda meets ORR endpoint in first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) reported that Keytruda pembrolizumab in combination with carboplatin/paclitaxel or Abraxane nab-paclitaxel met the secondary endpoint of improving overall response rate (ORR)

Read the full 265 word article

User Sign In